Media

Lonza Announces the Successful Results of the Rights Offering

FOR IMMEDIATE RELEASE

Contact:

Dirk Oehlers

Head Investor Relations
+41 61 316 8540
dirk.oehlers@lonza.com


Dominik Werner
Head Corporate Communications
+41 61 316 8798
dominik.werner@lonza.com

Constance Ward
Head External Communications
+41 61 316 8840
constance.ward@lonza.com

BASEL, SWITZERLAND– In connection with the capital increase by way of a rights offering as approved by the shareholders at Lonza's Annual General Meeting on 25 April 2017, Lonza offered a total of 16,548,612 newly issued shares to its existing shareholders.

By the end of the rights exercise period on 10 May 2017, 12.00 noon CEST, 99.25% of the rights had been exercised, corresponding to 16,424,010 newly issued shares. The 124,602 newly issued shares for which rights have not been exercised will be sold to the market..
 
The first day of trading of the newly issued shares on SIX Swiss Exchange is expected to be on 12 May 2017, and delivery of the newly issued shares against payment is expected to be on the same day.

The number of registered shares of Lonza after completion of the rights offering will amount to 74,468,752. The gross proceeds from the rights issue will be used to partially finance the acquisition of Capsugel S.A.


About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
 
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
 
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.


Return Home